Showing 1 - 20 results of 24,220 for search '(( 59 ((n_ decrease) OR (a decrease)) ) OR ( 50 ((mean decrease) OR (_ decrease)) ))', query time: 0.65s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4

    Exposure to low CO<sub>2</sub> levels decreases ER cholesterol levels. by Nityanand Bolshette (17396845)

    Published 2023
    “…<b>(B)</b> Bioluminescence recordings from the different conditions as depicted in <b>(A)</b>, the arrow indicates the time CO<sub>2</sub> was shifted from 5% to 1% (mean ± SE, <i>n</i> = 4 biological replicates per condition, AUC for 0 mM 0.34 ± 0.007, 1.59 ± 0.004 (<i>P</i> < 0.0001), 0.5 mM 1.00 ± 0.023, 2.68 ± 0.04 (<i>P</i> < 0.0001), 1 mM 1.66 ± 0.07, 3.34 ± 0.04 (<i>P</i> < 0.0001), 3 mM 2.06 ± 0.02, 2.79 ± 0.07 (<i>P</i> < 0.0001), 5 mM 2.02 ± 0.05, 2.43 ± 0.06 (<i>P</i> < 0.002), 7 mM 1.85 ± 0.01, 1.77 ± 0.02 (<i>P</i> < 0.02) two-sided Student’s <i>t</i> test). …”
  5. 5
  6. 6
  7. 7
  8. 8

    The GluN2B-C456Y mutation decreases recombinant NMDAR currents and alters receptor properties. by Wangyong Shin (6793040)

    Published 2020
    “…<p>(A) The GluN2B-C456Y mutation strongly decreases diheteromeric GluN1/GluN2B NMDAR currents in <i>Xenopus</i> oocytes. …”
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17

    Does Mean Platelet Volume Decrease in the presence of Coronary Artery Fistula? by Isa Sincer (7234577)

    Published 2019
    “…Several studies have shown the association between mean platelet volume (MPV) and cardiovascular diseases. …”
  18. 18

    GCase activity is significantly decreased in the brain and liver of the homozygous <i>GBA1</i> D409V KI mouse model at 4, 8, and 12 months of age. by Nicole K. Polinski (10947787)

    Published 2021
    “…In whole brain homogenate (A,C) and liver homogenate (B,D), GCase activity is significantly decreased in the <i>GBA1</i> D409V KI homozygous (HOM) mice as compared to C57Bl/6 wild type (WT) mice (n = 7/group). …”
  19. 19

    Table_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

    Published 2022
    “…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”
  20. 20

    Image_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

    Published 2022
    “…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”